Fundraising Overview - The company raised a total of RMB 1,283,564,291.24 through a non-public offering of 54,900,098 shares, with a net amount of RMB 1,276,238,913.79 after deducting issuance costs of RMB 7,325,377.45, all funds were received by February 14, 2023 [1][2] Fund Utilization - As of June 30, 2025, the company has utilized RMB 1,160,621,541.60 of the raised funds, with RMB 145,366,012.37 used in the current year, all allocated to fundraising projects [2][4] - The remaining balance in the fundraising account is RMB 149,471,571.45, which includes interest income after deducting bank fees and repayments of loans from the subsidiary [2][3] Fund Management - The company has established a dedicated account management system for the raised funds to ensure compliance with regulations and protect investor interests [2][3] - A tripartite supervision agreement was signed with several banks to manage the dedicated accounts for the raised funds [3] Project Financing - The company approved the use of raised funds to provide loans to its subsidiary, Xinhua Surgical Instruments Co., Ltd., for the expansion of high-end precision minimally invasive surgical instruments production, with a loan limit of RMB 208,725,900 [4] - The company has not used idle funds for temporary working capital or invested in financial products [4] Project Adjustments - The company has made adjustments to the timelines for certain fundraising projects due to delays in procurement, acceptance, and delivery, but these changes do not affect the project implementation entities or investment amounts [4][5] - The company has not changed the investment projects or transferred funds to external parties [4][5] Compliance and Disclosure - The company has complied with the relevant regulations regarding the management and use of raised funds, ensuring timely and accurate disclosures [4][5]

Core Viewpoint - The company reported a decline in revenue and net profit for the first half of 2025, attributed to reduced income from medical trade products, while maintaining a focus on innovation and market expansion in the medical device sector [2][3][14]. Company Overview and Financial Indicators - Company Name: Shandong Shinva Medical Instrument Co., Ltd. [2] - Stock Code: 600587 [2] - Total Revenue: CNY 4.79 billion, a decrease of 7.64% compared to the previous year [2][14]. - Total Profit: CNY 454.48 million, down 19.91% year-on-year [2][14]. - Net Profit Attributable to Shareholders: CNY 385.72 million, a decline of 20.35% [2][14]. - Net Assets: CNY 7.86 billion, an increase of 3.41% from the previous year [2][14]. - Total Assets: CNY 15.35 billion, a decrease of 1.15% [2][14]. Industry Context - The medical device industry is expected to achieve significant breakthroughs in high-end imaging equipment, molecular diagnostics, and smart wearables, with a projected market size exceeding CNY 1.8 trillion by 2030 [3][14]. - The industry is transitioning towards high-quality and intelligent development, supported by government policies that promote innovation and streamline regulatory processes for advanced medical devices [3][14]. Business Operations - The company operates in two main sectors: medical devices and pharmaceutical equipment, with a focus on integrating services and trade to enhance market position [3][14]. - The medical device segment has developed nine advanced product lines, including infection control and surgical instruments, and is expanding its smart service offerings [3][14]. - The company has made significant advancements in technology, including the launch of new products such as the intelligent ring accelerator and various sterilization devices [3][14]. Research and Development - R&D investment reached CNY 202 million, an increase of 8.88% year-on-year, reflecting the company's commitment to innovation [14]. - The company has launched over 100 key technology innovation projects, focusing on upgrading existing products and developing new ones [14][15]. - Collaborations with academic institutions have been strengthened to foster innovation and technological advancements [15][16]. Market Expansion - The company is actively expanding its international market presence, with a focus on enhancing brand recognition and establishing stable sales channels in over 10 countries [6][17]. - The company has adopted a dual circulation development strategy, promoting both domestic and international market growth [10][17]. Financial Performance Analysis - The decline in revenue is primarily due to reduced income from medical trade products, while operating costs have also decreased [14]. - The company has improved its cash flow from operating activities, with a net cash flow of CNY 242.75 million, up 76.86% from the previous year [14].

Core Viewpoint - The financial performance of Shandong Xinhua Medical Equipment Co., Ltd. has shown a decline in revenue and profit for the first half of 2025 compared to the previous year, indicating potential challenges in the company's operations and market conditions [1]. Financial Summary - Total assets at the end of the reporting period amounted to CNY 15.35 billion, a decrease of 1.15% from the previous year [1]. - Net assets attributable to shareholders increased to CNY 7.86 billion, reflecting a growth of 3.41% year-on-year [1]. - Operating revenue for the period was CNY 4.79 billion, down 7.64% compared to CNY 5.19 billion in the same period last year [1]. - Total profit decreased by 19.91% to CNY 454.48 million from CNY 567.47 million [1]. - Net profit attributable to shareholders fell by 20.35% to CNY 385.72 million, compared to CNY 484.26 million in the previous year [1]. - The net profit after deducting non-recurring gains and losses was CNY 242.75 million [1]. - The net cash flow from operating activities increased significantly by 76.86% to CNY 137.26 million [1]. - The weighted average return on net assets decreased by 1.51 percentage points to 4.99% [1]. - Basic and diluted earnings per share dropped by 35.35% to CNY 0.64 [1]. Shareholder Information - The total number of shareholders at the end of the reporting period was 39,279 [1]. - Major shareholders include Shandong Yiyang Health Industry Development Group Co., Ltd. with a holding of 28.91% and Shandong State-owned Assets Investment Holdings Co., Ltd. with 4.15% [2].

Group 1 - The core viewpoint of the article is that Xinhua Medical (SH 600587) held its 20th meeting of the 11th Board of Directors on August 27, 2025, where it reviewed the full and summary reports for the first half of 2025 [1] - For the year 2024, Xinhua Medical's revenue composition is as follows: medical devices accounted for 68.46%, pharmaceutical equipment for 21.66%, medical services for 8.32%, and other businesses for 1.56% [1] - As of the time of reporting, Xinhua Medical has a market capitalization of 9.9 billion yuan [1]

证券代码：600587 证券简称：新华医疗 编号：临 2025-036 山东新华医疗器械股份有限公司 第十一届董事会第二十次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假 记载、误导性陈述或者重大遗漏负连带责任。 一、董事会会议召开情况 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）第十 一届董事会第二十次会议于 2025 年 8 月 17 日以书面或通讯方式通知全体董事， 据此通知，会议于 2025 年 8 月 27 日在公司三楼会议室召开。会议以现场与通讯 相结合的方式召开，会议应到董事 11 名，实到 11 名，公司监事和高级管理人员 列席了会议，会议由董事长王玉全先生主持，会议程序符合《公司法》和《公司 章程》的规定。 二、董事会会议审议情况 （一）审议通过《公司 2025 年半年度报告全文及摘要》 董事会审计委员会审议通过了《2025 年半年度报告全文及摘要》。 会议审议通过公司根据《上海证券交易所股票上市规则》、上海证券交易所 关于上市公司定期报告编制的要求等其他相关法律法规及规范性法律文件编制 的《公司 2025 年半年度报告全文及摘要》。 公司 ...

Group 1 - The core viewpoint of the article is that Xinhua Medical (600587.SH) reported a decline in both revenue and net profit for the first half of 2025 compared to the previous year [1] Group 2 - The company achieved total operating revenue of 4.79 billion yuan, representing a year-on-year decrease of 7.64% [1] - The net profit attributable to shareholders of the parent company was 386 million yuan, down 20.35% year-on-year [1] - The basic earnings per share were reported at 0.64 yuan [1]

山东新华医疗器械股份有限公司 地 址：山东省淄博市高新技术产业开发区新华医疗科技园 邮 编：255086 电子邮箱：dqgzb@shinva.com 联系电话：0533-3587734 新华医疗公众号 新华医疗红色家园 山发海岳环境科技（山东）股份有限公司 编制设计 2024 环境 、社会和公司治理(ESG)报告 ENVIRONMENTAL SOCIAL AND GOVERNANCE (ESG) REPORT 山东新华医疗器械股份有限公司环境︑ 社会和公司治理ESG报告2024 品牌建设 百年匠心 目录 精准定位 战略赋能 | 责任专题： | | | | --- | --- | --- | | 新华八十一载 为健康创新界 | | 卓越品质 服务健康 | | 13 八十一载 新华风采 | 45 | 坚持质量制胜 | | 13 聚焦主业 协同发展 | 54 | 践行卓越服务 | | 17 | 58 | 保障数据安全 | | 18 | 59 | 可持续供应链 | 董事长致辞 关于本报告 走进新华医疗 未来展望 01 03 05 123 附录 125 可持续发展治理 | 21 | ESG战略 | | --- | -- ...

证券代码：600587 证券简称：新华医疗 公告编号：临2025-038 经中国证券监督管理委员会《关于核准山东新华医疗器械股份有限公司非公 开发行股票的批复》（证监许可[2022]1223 号）核准，新华医疗非公开发行人 民币普通股（A 股）54,900,098 股，募集资金总额为人民币 1,283,564,291.24 元，扣除各项不含税发行费用人民币 7,325,377.45 元后，实际募集资金净额为 人民币 1,276,238,913.79 元，上述资金已于 2023 年 2 月 14 日全部到位。天健 会计师事务所（特殊普通合伙）对公司本次非公开发行新股的资金到位情况进行 了审验，并于 2023 年 2 月 21 日出具了《验资报告》（天健验【2023】60 号）。 公司对募集资金采取了专户存储管理。 （二）募集资金使用和结余情况 截至 2025 年 6 月 30 日，公司累计使用募集资金人民币 1,160,621,541.60 元，其中：本年度使用 145,366,012.37 元，均投入募集资金项目。 截至 2025 年 6 月 30 日，公司累计使用金额人民币 1,160,621,541.60 ...

证券代码：600587 证券简称：新华医疗 编号：临 2025-037 山东新华医疗器械股份有限公司 第十一届监事会第二十次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、 误导性陈述或者重大遗漏负连带责任。 一、监事会会议召开情况 山东新华医疗器械股份有限公司（以下简称公司）第十一届监事会第二十次 会议于 2025 年 8 月 17 日以通讯和书面方式发出通知，据此通知，会议于 2025 年 8 月 27 日在公司三楼会议室召开，应到监事 3 名，实到 3 名。会议由监事会 主席牟乐海先生召集和主持，符合《公司法》和《公司章程》规定。 二、监事会会议审议情况 （一）审议通过《公司 2025 年半年度报告全文及摘要》，并对公司 2025 年 半年度报告全文及摘要发表审核意见 公司监事会根据《证券法》、《公开发行证券的公司信息披露内容与格式准则 第 3 号——半年度报告的内容与格式（2025 年修订）》、《上海证券交易所股票上 市规则（2025 年 4 月修订）》、《上海证券交易所上市公司自律监管指南第 2 号— —业务办理（2025 年 4 月修订）》等与半年度报告编制有 ...

山东新华医疗器械股份有限公司 第十一届董事会第二十次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假 记载、误导性陈述或者重大遗漏负连带责任。 证券代码：600587 证券简称：新华医疗 编号：临 2025-036 一、董事会会议召开情况 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）第十 一届董事会第二十次会议于 2025 年 8 月 17 日以书面或通讯方式通知全体董事， 据此通知，会议于 2025 年 8 月 27 日在公司三楼会议室召开。会议以现场与通讯 相结合的方式召开，会议应到董事 11 名，实到 11 名，公司监事和高级管理人员 列席了会议，会议由董事长王玉全先生主持，会议程序符合《公司法》和《公司 章程》的规定。 二、董事会会议审议情况 （一）审议通过《公司 2025 年半年度报告全文及摘要》 公司 2025 年半年度募集资金存放与使用情况符合《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》等相关法律、法规、规章及其 他规范性文件的规定。公司对募集资金进行了专户储存和专项使用，并及时履行 了相关信息披露义务，募集资金具体使用 ...